Patents Assigned to BALIOPHARM AG
  • Monovalent anti-huTNFR1 antibodies, encoding nucleic acids thereof and methods of treatment thereof
    Patent number: 10689452
    Abstract: The invention provides for an inhibitor of the huTNFRI receptor which is a human or humanized antibody construct that monovalently recognizes huTNFRI through an antigen-binding moiety, which is characterized by specific CDR sequences, a pharmaceutical preparation thereof, method of producing the inhibitor and the medical use of the inhibitor.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: June 23, 2020
    Assignees: UNIVERSITÄT STUTTGART, BALIOPHARM AG
    Inventors: Roland Kontermann, Klaus Pfizenmaier, Fabian Richter, Kirstin Zettlitz, Peter Scheurich, Andreas Herrmann
  • Recombinant bispecific antibody binding to CD20 and CD95
    Patent number: 10590202
    Abstract: A bispecific antibody format, which comprises a) a Fab fragment comprising a first binding site for a first antigen; b) an scFv fragment comprising a second binding site for a second antigen; and c) a CH2 domain, wherein the Fab fragment and the scFv fragment are linked via the CH2 domain, wherein the first antigen is CD95 and the second antigen is CD20; or the first antigen is CD20 and the second antigen is CD95.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: March 17, 2020
    Assignee: BALIOPHARM AG
    Inventors: Andreas Herrmann, Ludger Grosse-Hovest
  • Anti-huTNFR1 antibody and methods of use thereof for treatment
    Patent number: 8859739
    Abstract: The disclosure to an anti-huTNFR1 antibody of the IgG1 type, which has a modified Fc region deficient in mediating effector function, a pharmaceutical preparation comprising such antibody, and an anti-huTNFR1 antibody of the IgG1 type for use as a TNF antagonist without forming an agonistic TNFR1 signalling complex, as an alternative to treatment with an anti-TNF therapeutic.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: October 14, 2014
    Assignee: Baliopharm AG
    Inventors: Roland Kontermann, Klaus Pfizenmaier, Andreas Herrmann, Kirstin Zettlitz
  • ANTI-huTNFR1 ANTIBODY
    Publication number: 20130251707
    Abstract: The disclosure to an anti-huTNFR1 antibody of the IgG1 type, which has a modified Fc region deficient in mediating effector function, a pharmaceutical preparation comprising such antibody, and an anti-huTNFR1 antibody of the IgG1 type for use as a TNF antagonist without forming an agonistic TNFR1 signalling complex, as an alternative to treatment with an anti-TNF therapeutic.
    Type: Application
    Filed: September 16, 2011
    Publication date: September 26, 2013
    Applicant: BALIOPHARM AG
    Inventors: Roland Kontermann, Klaus Pfizenmaier, Andreas Herrmann, Kirstin Zettlitz